NSRX
Price:
$6.85
Market Cap:
$62.06M
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
Industry
Biotechnology
IPO Date
2025-08-13
Stock Exchange
AMEX
Ticker
NSRX
According to Nasus Pharma Ltd.’s latest financial reports and current stock price. The company's current ROE is 0%. This represents a change of 0% compared to the average of 0% of the last 4 quarters.
The mean historical ROE of Nasus Pharma Ltd. over the last ten years is 0%. The current 0% ROE has changed 0% with respect to the historical average. Over the past ten years (40 quarters), NSRX's ROE was at its highest in in the June 2024 quarter at 0%. The ROE was at its lowest in in the June 2024 quarter at 0%.
Average
0%
Median
0%
Minimum
0%
Maximum
0%
Discovering the peaks and valleys of Nasus Pharma Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 0%
Minimum Annual Increase = 0%
Minimum Annual ROE = 0%
| Year | ROE | Change |
|---|---|---|
| 2024 | 0% | 0% |
| 2023 | 0% | 0% |
The current ROE of Nasus Pharma Ltd. (NSRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
0%
5-year avg
0%
10-year avg
0%
Nasus Pharma Ltd.’s ROE is greater than Lite Strategy, Inc. (-27.11%), greater than Nutriband Inc. (-131.40%), greater than Adicet Bio, Inc. (-68.48%), greater than TScan Therapeutics, Inc. (-63.84%), greater than XBiotech Inc. (-16.73%), less than Fortress Biotech, Inc. (19.24%), greater than Gain Therapeutics, Inc. (-289.11%), greater than CervoMed Inc. (-59.15%), greater than Acrivon Therapeutics, Inc. Common Stock (-53.71%), greater than Adagene Inc. (-86.91%),
| Company | ROE | Market cap |
|---|---|---|
| -27.11% | $62.18M | |
| -131.40% | $55.69M | |
| -68.48% | $44.95M | |
| -63.84% | $60.81M | |
| -16.73% | $74.69M | |
| 19.24% | $88.14M | |
| -289.11% | $128.73M | |
| -59.15% | $83.53M | |
| -53.71% | $76.84M | |
| -86.91% | $74.11M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nasus Pharma Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nasus Pharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Nasus Pharma Ltd.'s ROE?
How is the ROE calculated for Nasus Pharma Ltd. (NSRX)?
What is the highest ROE for Nasus Pharma Ltd. (NSRX)?
What is the 3-year average ROE for Nasus Pharma Ltd. (NSRX)?
What is the 5-year average ROE for Nasus Pharma Ltd. (NSRX)?
How does the current ROE for Nasus Pharma Ltd. (NSRX) compare to its historical average?